{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:43:41Z","timestamp":1792079021009,"version":"4.4.0"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.pharmthera.2020.107477","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T19:37:57Z","timestamp":1578512277000},"page":"107477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":154,"special_numbering":"C","title":["The therapeutic potential of second and third generation CB1R antagonists"],"prefix":"10.1016","volume":"208","author":[{"given":"Resat","family":"Cinar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malliga R.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107477_bb0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","article-title":"The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake","volume":"7","author":"Addy","year":"2008","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/03602532.2018.1428341","article-title":"The future of type 1 cannabinoid receptor allosteric ligands","volume":"50","author":"Alaverdashvili","year":"2018","journal-title":"Drug Metabolism Reviews"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0015","doi-asserted-by":"crossref","first-page":"13692","DOI":"10.1039\/C4RA17274D","article-title":"4-Cyano-5-(2-thiophenyl)-pyrazoles are high affinity CB1receptor ligands","volume":"5","author":"Altomonte","year":"2015","journal-title":"RSC Advances"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0020","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1021\/acs.jmedchem.9b00727","article-title":"Functionalized 6-(piperidin-1-yl)-8,9-diphenyl purines as peripherally restricted inverse agonists of the CB1 receptor","volume":"62","author":"Amato","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0025","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1021\/acs.jmedchem.7b01820","article-title":"Blocking alcoholic steatosis in mice with a peripherally restricted purine antagonist of the type 1 cannabinoid receptor","volume":"61","author":"Amato","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0030","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/labinvest.2015.67","article-title":"The role of iNOS in cholesterol-induced liver fibrosis","volume":"95","author":"Anavi","year":"2015","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0035","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/hep.22278","article-title":"Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration","volume":"47","author":"Aram","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0040","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/oby.2010.352","article-title":"Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance","volume":"19","author":"Aronne","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0045","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/db09-1336","article-title":"Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy","volume":"59","author":"Barutta","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0050","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/ndt\/gfx010","article-title":"Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy","volume":"32","author":"Barutta","year":"2017","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-018-0975-7","article-title":"Cannabinoid receptors in diabetic kidney disease","volume":"18","author":"Barutta","year":"2018","journal-title":"Current Diabetes Reports"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0065","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/89953","article-title":"Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis","volume":"7","author":"Batkai","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0070","doi-asserted-by":"crossref","first-page":"H1689","DOI":"10.1152\/ajpheart.00538.2007","article-title":"Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats","volume":"293","author":"Batkai","year":"2007","journal-title":"American Journal of Physiology Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0075","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/01.CIR.0000143230.23252.D2","article-title":"Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension","volume":"110","author":"Batkai","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0080","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nn.3053","article-title":"Mitochondrial CB(1) receptors regulate neuronal energy metabolism","volume":"15","author":"Benard","year":"2012","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","article-title":"The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells","volume":"63","author":"Bensaid","year":"2003","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00005344-200304000-00020","article-title":"Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle","volume":"41","author":"Bonz","year":"2003","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1165\/rcmb.2014-0331OC","article-title":"Protection from radiation-induced pulmonary fibrosis by peripheral targeting of cannabinoid receptor-1","author":"Bronova","year":"2015","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/35040576","article-title":"Bidirectional control of airway responsiveness by endogenous cannabinoids","volume":"408","author":"Calignano","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrendo.2015.211","article-title":"Endocannabinoids--at the crossroads between the gut microbiota and host metabolism","volume":"12","author":"Cani","year":"2016","journal-title":"Nature Reviews. Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0110","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2009.02137.x","article-title":"Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis","volume":"30","author":"Caraceni","year":"2010","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0115","doi-asserted-by":"crossref","first-page":"9920","DOI":"10.1021\/jm401158e","volume":"56","author":"Chang","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0120","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fphar.2017.00707","article-title":"Novel peripherally restricted cannabinoid 1 receptor selective antagonist TXX-522 with prominent weight-loss efficacy in diet induced obese mice","volume":"8","author":"Chen","year":"2017","journal-title":"Frontiers in Pharmacology"},{"issue":"877\u2013889","key":"10.1016\/j.pharmthera.2020.107477_bb0125","article-title":"Glutamate signaling in hepatic stellate cells drives alcoholic steatosis","volume":"30","author":"Choi","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0135","doi-asserted-by":"crossref","first-page":"16957","DOI":"10.1016\/S0021-9258(19)84800-7","article-title":"Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts. A role for lipid peroxidation?","volume":"264","author":"Chojkier","year":"1989","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0140","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.bmcl.2013.06.066","article-title":"Peripherally restricted CB1 receptor blockers","volume":"23","author":"Chorvat","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0145","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1016\/j.bmcl.2012.08.004","article-title":"JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities","volume":"22","author":"Chorvat","year":"2012","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0150","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0155","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92281","article-title":"Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis","volume":"2","author":"Cinar","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hep.26606","article-title":"Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides","volume":"59","author":"Cinar","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.pharmthera.2020.107477_bb0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87336","article-title":"Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis","volume":"1","author":"Cinar","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0170","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1476-5381.2010.00908.x","article-title":"A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents","volume":"161","author":"Cluny","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0175","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pbb.2005.01.022","article-title":"Endocannabinoid system and alcohol addiction: pharmacological studies","volume":"81","author":"Colombo","year":"2005","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0180","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1172\/JCI17725","article-title":"The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis","volume":"112","author":"Cota","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0185","first-page":"2052","article-title":"Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells","volume":"61","author":"Dai","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0190","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall\u2019Ozzo","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0195","doi-asserted-by":"crossref","first-page":"7279","DOI":"10.1111\/jcmm.14570","article-title":"The cannabinoid receptor 1 is involved in renal fibrosis during chronic allograft dysfunction: Proof of concept","volume":"23","author":"Dao","year":"2019","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0200","doi-asserted-by":"crossref","first-page":"G506","DOI":"10.1152\/ajpgi.00304.2007","article-title":"Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1\/redox factor 1 and AP-1 activation","volume":"294","author":"DeMorrow","year":"2008","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0205","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0210","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","article-title":"Effect of rimonabant on the high-triglyceride\/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial","volume":"29","author":"Despres","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0215","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1124\/jpet.116.236539","article-title":"Two Janus cannabinoids that are both CB2 agonists and CB1 antagonists","volume":"360","author":"Dhopeshwarkar","year":"2017","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0220","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery","volume":"56","author":"Di","year":"2013","journal-title":"Miniperspective. Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0225","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptin-regulated endocannabinoids are involved in maintaining food intake","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0230","doi-asserted-by":"crossref","first-page":"12904","DOI":"10.1073\/pnas.1104675108","article-title":"Endocannabinoid signal in the gut controls dietary fat intake","volume":"108","author":"DiPatrizio","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2009.01.004","article-title":"Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis","volume":"137","author":"Domenicali","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0240","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1021\/ml3000325","article-title":"Design of a potent CB1 receptor antagonist series: potential scaffold for peripherally-targeted agents","volume":"3","author":"Dow","year":"2012","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0245","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/dom.13497","article-title":"Cannabinoid-1 receptor regulates mitochondrial dynamics and function in renal proximal tubular cells","volume":"21","author":"Drori","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0250","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00125-008-1240-4","article-title":"Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle","volume":"52","author":"Eckardt","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0255","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1124\/jpet.107.127498","article-title":"Endotoxemia-mediated induction of cardiac inducible nitric-oxide synthase expression accounts for the hypotensive effect of ethanol in female rats","volume":"324","author":"El-Mas","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0260","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/labinvest.3780436","article-title":"Cell-specific nitric oxide synthase-isoenzyme expression and regulation in response to endotoxin in intact rat lungs","volume":"82","author":"Ermert","year":"2002","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0265","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0270","article-title":"Leptospira Interrogans induces fibrosis in the mouse kidney through Inos-dependent, TLR- and NLR-independent signaling pathways","volume":"8","author":"Fanton d\u2019Andon","year":"2014","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0275","first-page":"1635","article-title":"Role of snail activation in alcohol-induced iNOS-mediated disruption of intestinal epithelial cell permeability","volume":"35","author":"Forsyth","year":"2011","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0280","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/0929867324666170911170020","article-title":"The role of cannabinoid receptors in renal diseases","volume":"25","author":"Francois","year":"2018","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0285","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1021\/jm201731z","article-title":"Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity","volume":"55","author":"Fulp","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0290","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1021\/jm301181r","article-title":"Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists","volume":"55","author":"Fulp","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0295","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1016\/j.bmcl.2011.08.032","article-title":"Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity","volume":"21","author":"Fulp","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0300","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FBP.0000000000000027","article-title":"In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569","volume":"25","author":"Gamage","year":"2014","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0305","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1016\/j.ejmech.2011.08.030","article-title":"Asymmetric synthesis and biological evaluation of N-cyclohexyl-4-[1-(2,4-dichlorophenyl)-1-(p-tolyl)methyl]piperazine-1-carboxamide as hCB1 receptor antagonists","volume":"46","author":"Gao","year":"2011","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0310","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjp.0706331","article-title":"Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats","volume":"146","author":"Gaskari","year":"2005","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0315","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1073\/pnas.90.8.3491","article-title":"Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes","volume":"90","author":"Geller","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0320","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-6-58","article-title":"Inhibition or knock out of inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury","volume":"6","author":"Genovese","year":"2005","journal-title":"Respiratory Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-009-1704-3","article-title":"Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers","volume":"208","author":"George","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0330","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jpba.2016.11.003","article-title":"Targeted proteomics of cannabinoid receptor CB1 and the CB1b isoform","volume":"144","author":"Ghosh","year":"2017","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1089-8603(02)00102-7","article-title":"Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice","volume":"7","author":"Giri","year":"2002","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0340","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.cmet.2019.04.012","article-title":"Targeting peripheral CB1 receptors reduces ethanol intake via a gut-brain axis","volume":"29","author":"Godlewski","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0345","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.1523\/JNEUROSCI.22-21-09612.2002","article-title":"A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding","volume":"22","author":"Gomez","year":"2002","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/srep33302","article-title":"Human CB1 receptor isoforms, present in hepatocytes and beta-cells, are involved in regulating metabolism","volume":"6","author":"Gonzalez-Mariscal","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2015.12.015","article-title":"Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice","volume":"423","author":"Gonzalez-Mariscal","year":"2016","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0360","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s00125-018-4576-4","article-title":"Absence of cannabinoid 1 receptor in beta cells protects against high-fat\/high-sugar diet-induced beta cell dysfunction and inflammation in murine islets","volume":"61","author":"Gonzalez-Mariscal","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0365","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1096\/fj.201801145R","article-title":"Muscle cannabinoid 1 receptor regulates Il-6 and myostatin expression, governing physical performance and whole-body metabolism","volume":"33","author":"Gonzalez-Mariscal","year":"2019","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0370","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/glia.23314","article-title":"Localization of the cannabinoid type-1 receptor in subcellular astrocyte compartments of mutant mouse hippocampus","volume":"66","author":"Gutierrez-Rodriguez","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0375","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1096\/fj.201801152RR","article-title":"A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice","volume":"33","author":"Han","year":"2019","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0380","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/dom.13350","article-title":"Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity","volume":"20","author":"Han","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0385","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/01.CIR.93.6.1087","article-title":"Expression of inducible nitric oxide synthase in human heart failure","volume":"93","author":"Haywood","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0390","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.12186","article-title":"Role of nitric oxide synthase genes in hepatitis E virus infection","volume":"21","author":"Hazam","year":"2014","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0395","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nature20127","article-title":"A cannabinoid link between mitochondria and memory","volume":"539","author":"Hebert-Chatelain","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0400","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/hep.1840200621","article-title":"Induction of hepatic Ito cell nitric oxide production after acute endotoxemia","volume":"20","author":"Helyar","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0405","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1681\/ASN.2017040371","article-title":"Modulation of renal GLUT2 by the cannabinoid-1 receptor: implications for the treatment of diabetic nephropathy","volume":"29","author":"Hinden","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0410","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1021\/jm060642i","article-title":"Structure-brain exposure relationships","volume":"49","author":"Hitchcock","year":"2006","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0415","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1016\/j.bmcl.2010.06.017","article-title":"Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif","volume":"20","author":"Hortala","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0420","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/dom.12447","article-title":"A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis","volume":"17","author":"Hsiao","year":"2015","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0425","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nature23272","article-title":"Crystal structures of agonist-bound human cannabinoid receptor CB1","volume":"547","author":"Hua","year":"2017","journal-title":"Nature"},{"issue":"750\u2013762","key":"10.1016\/j.pharmthera.2020.107477_bb0430","article-title":"Crystal structure of the human cannabinoid receptor CB1","volume":"167","author":"Hua","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0435","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760190062","article-title":"Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model","volume":"114","author":"Issa","year":"2019","journal-title":"Mem\u00f3rias do Instituto Oswaldo Cruz"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0440","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/acs.jmedchem.6b01504","article-title":"Design, synthesis, and biological evaluation of novel, non-brain-penetrant, hybrid cannabinoid CB1R inverse agonist\/inducible nitric oxide synthase (iNOS) inhibitors for the treatment of liver fibrosis","volume":"60","author":"Iyer","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0445","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/mol.115.098541","article-title":"Structural basis of species-dependent differential affinity of 6-alkoxy-5-aryl-3-pyridinecarboxamide cannabinoid-1 receptor antagonists","volume":"88","author":"Iyer","year":"2015","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb3010","series-title":"Aryl-substituted imidazolidine-2,4-diones, method for the production thereof, medicaments containing said compounds and use thereof. WO 2009\/097999 A1","author":"Jaehne","year":"2011"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0455","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/gast.2001.20875","article-title":"Nitric oxide-mediated inhibition of DNA repair potentiates oxidative DNA damage in cholangiocytes","volume":"120","author":"Jaiswal","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0460","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1096\/fj.04-3177fje","article-title":"The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance","volume":"19","author":"Jbilo","year":"2005","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0465","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmet.2007.12.007","article-title":"Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver","volume":"7","author":"Jeong","year":"2008","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0470","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.24733","article-title":"Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants","volume":"55","author":"Jourdan","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0475","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nm.3265","article-title":"Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes","volume":"19","author":"Jourdan","year":"2013","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0480","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.molmet.2017.08.011","article-title":"Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice","volume":"6","author":"Jourdan","year":"2017","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0485","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/dom.13150","article-title":"Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy","volume":"20","author":"Jourdan","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0490","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2337\/db16-1199","article-title":"Developmental role of macrophage cannabinoid-1 receptor signaling in type-2 diabetes","volume":"66","author":"Jourdan","year":"2017","journal-title":"Diabetes."},{"key":"10.1016\/j.pharmthera.2020.107477_bb0495","first-page":"E5420","article-title":"Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy","volume":"111","author":"Jourdan","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0500","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1152\/ajpendo.00196.2015","article-title":"CB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors","volume":"309","author":"Kabir","year":"2015","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0505","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.lfs.2008.03.018","article-title":"Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta","volume":"82","author":"Kalayarasan","year":"2008","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0510","doi-asserted-by":"crossref","first-page":"104483","DOI":"10.1016\/j.yrtph.2019.104483","article-title":"Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis","volume":"109","author":"Kale","year":"2019","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0515","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.22950","article-title":"Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis","volume":"50","author":"Karlmark","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0520","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0525","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1524-475X.2007.00308.x","article-title":"New strategy for the antifibrotic therapy with oral administration of FR260330 (a selective inducible nitric oxide synthase inhibitor) in rat experimental liver cirrhosis","volume":"15","author":"Kikuchi","year":"2007","journal-title":"Wound Repair and Regeneration"},{"key":"10.1016\/j.pharmthera.2020.107477_bb3005","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41467-017-02325-2","article-title":"Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4\u2013MD2 complex.","volume":"8","author":"Kim","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0530","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/db10-1550","article-title":"Cannabinoids inhibit insulin receptor signaling in pancreatic beta-cells","volume":"60","author":"Kim","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0535","doi-asserted-by":"crossref","first-page":"ra23","DOI":"10.1126\/scisignal.2002519","article-title":"Cannabinoids induce pancreatic beta-cell death by directly inhibiting insulin receptor activation","volume":"5","author":"Kim","year":"2012","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0540","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.12141","article-title":"Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects","volume":"76","author":"Klumpers","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011376","article-title":"Hyperleptinemia is required for the development of leptin resistance","volume":"5","author":"Knight","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0550","series-title":"Cannabinoid Receptor Mediating Compounds, US 9765031 B2","author":"Kunos","year":"2017"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2008.10.001","article-title":"Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?","volume":"30","author":"Kunos","year":"2009","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0560","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00109-011-0824-5","article-title":"Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system","volume":"90","author":"Lazzerini","year":"2012","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0565","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/ki.2015.63","article-title":"Cannabinoid receptor 1 is a major mediator of renal fibrosis","volume":"88","author":"Lecru","year":"2015","journal-title":"Kidney International"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0570","series-title":"1,5-diaryl-4,5-dihydro-1H-pyrazole-3-carboxamidine derivatives as cannabinoid CB1 receptor antagonist, method for preparing same, and pharmaceutical composition comprising same, WO\/2014\/208939","author":"Lee","year":"2014"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0575","first-page":"201","article-title":"Role of nitric oxide in the regulation of fibrogenic factors in experimental liver fibrosis in mice","volume":"26","author":"Leung","year":"2011","journal-title":"Histology and Histopathology"},{"issue":"459\u2013467","key":"10.1016\/j.pharmthera.2020.107477_bb0580","article-title":"Crystal structure of the human cannabinoid receptor CB2","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0585","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00109-014-1125-6","article-title":"Cannabinoid receptor 1 disturbance of PPARgamma2 augments hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli","volume":"92","author":"Lin","year":"2014","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0590","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.yjmcc.2015.06.010","article-title":"CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia","volume":"85","author":"Lin","year":"2015","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0595","doi-asserted-by":"crossref","first-page":"45034","DOI":"10.1074\/jbc.M306062200","article-title":"Lipopolysaccharide induces anandamide synthesis in macrophages via CD14\/MAPK\/phosphoinositide 3-kinase\/NF-kappaB independently of platelet-activating factor","volume":"278","author":"Liu","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"Pt 3","key":"10.1016\/j.pharmthera.2020.107477_bb0600","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1042\/bj3460835","article-title":"Functional CB1 cannabinoid receptors in human vascular endothelial cells","volume":"346","author":"Liu","year":"2000","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0605","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/hep.30364","article-title":"Cannabinoid-1 receptor antagonism improves glycemic control and increases energy expenditure through sirtuin-1\/mechanistic target of rapamycin complex 2 and 5\u2019adenosine monophosphate-activated protein kinase signaling","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0610","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.01.032","article-title":"Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice","volume":"142","author":"Liu","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0615","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.ijo.0802847","article-title":"Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)\/Lep(ob) mice","volume":"29","author":"Liu","year":"2005","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0620","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/labinvest.2009.104","article-title":"Inhibition of nitric oxide synthesis during induced cholestasis ameliorates hepatocellular injury by facilitating S-nitrosothiol homeostasis","volume":"90","author":"Lopez-Sanchez","year":"2010","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0625","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bmcl.2008.12.059","article-title":"Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice","volume":"19","author":"LoVerme","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0630","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1073\/pnas.89.15.6711","article-title":"Cloned and expressed macrophage nitric oxide synthase contrasts with the brain enzyme","volume":"89","author":"Lowenstein","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0635","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2362.2008.01941.x","article-title":"Inhibition of inducible nitric oxide synthase activity prevents liver recovery in rat thioacetamide-induced fibrosis reversal","volume":"38","author":"Lukivskaya","year":"2008","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0640","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","article-title":"Endocannabinoid signaling at the periphery: 50 years after THC","volume":"36","author":"Maccarrone","year":"2015","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0645","series-title":"Quinazoline derivatives useful AS CB-1 inverse agonists, US 2016\/0068512 A1","author":"Macielag","year":"2016"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0650","series-title":"Cinnoline derivatives useful as CB-1 receptor inverse agonists, US 2016\/0200719 A1","author":"Macielag","year":"2016"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0655","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728222.11.3.403","article-title":"Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases","volume":"11","author":"Mallat","year":"2007","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0660","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1113\/EP086594","article-title":"Evaluation of inducible nitric oxide synthase inhibition on kidney function and structure in high-fat diet-induced kidney disease","volume":"103","author":"Martin","year":"2018","journal-title":"Experimental Physiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0665","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1016\/j.bmcl.2016.09.025","article-title":"Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists","volume":"26","author":"Matthews","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0670","doi-asserted-by":"crossref","first-page":"H1658","DOI":"10.1152\/ajpheart.00214.2016","article-title":"Chronic plus binge ethanol feeding induces myocardial oxidative stress, mitochondrial and cardiovascular dysfunction, and steatosis","volume":"310","author":"Matyas","year":"2016","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0675","doi-asserted-by":"crossref","first-page":"17161","DOI":"10.1073\/pnas.0134112100","article-title":"Distribution of nitric oxide synthase in normal and cirrhotic human liver","volume":"99","author":"McNaughton","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0680","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15154-6","article-title":"Blockade of CB1 cannabinoid receptor alters gut microbiota and attenuates inflammation and diet-induced obesity","volume":"7","author":"Mehrpouya-Bahrami","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0685","doi-asserted-by":"crossref","first-page":"243","DOI":"10.35946\/arcr.v38.2.07","article-title":"Alcohol and the lung","volume":"38","author":"Mehta","year":"2017","journal-title":"Alcohol Research: Current Reviews"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0690","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fphys.2016.00476","article-title":"Cannabinoid CB1 receptors are localized in striated muscle mitochondria and regulate mitochondrial respiration","volume":"7","author":"Mendizabal-Zubiaga","year":"2016","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0695","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1089\/can.2015.0005","article-title":"Allosteric modulators of the CB1 cannabinoid receptor: a structural update review","volume":"1","author":"Morales","year":"2016","journal-title":"Cannabis and Cannabinoid Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0700","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-010-1790-2","article-title":"Randomized, controlled, double-blind trial of taranabant for smoking cessation","volume":"209","author":"Morrison","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0705","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/msb.2010.46","article-title":"The endocannabinoid system links gut microbiota to adipogenesis","volume":"6","author":"Muccioli","year":"2010","journal-title":"Molecular Systems Biology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0710","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/hep.27686","article-title":"Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms","volume":"61","author":"Mukhopadhyay","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0715","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2007.03.057","article-title":"Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity","volume":"50","author":"Mukhopadhyay","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0720","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/cvr\/cvp369","article-title":"CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes","volume":"85","author":"Mukhopadhyay","year":"2010","journal-title":"Cardiovascular Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0725","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1152\/ajpendo.00374.2016","article-title":"Overactivation of the endocannabinoid system alters the antilipolytic action of insulin in mouse adipose tissue","volume":"313","author":"Muller","year":"2017","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0730","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.4049\/jimmunol.0904214","article-title":"Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation","volume":"185","author":"Naura","year":"2010","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0735","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2014.09.015","article-title":"Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis","volume":"62","author":"Navarro","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0740","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00213-005-0234-x","article-title":"The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats","volume":"184","author":"Need","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0745","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.510300433","article-title":"CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells","volume":"30","author":"Nieto","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0750","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0755","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-015-0269-3","article-title":"Deficiency of iNOS-derived NO accelerates lipid accumulation-independent liver fibrosis in non-alcoholic steatohepatitis mouse model","volume":"15","author":"Nozaki","year":"2015","journal-title":"BMC Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0760","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"Osei-Hyiaman","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0765","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1172\/JCI34827","article-title":"Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice","volume":"118","author":"Osei-Hyiaman","year":"2008","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0770","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1089\/end.2009.0035","article-title":"Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression","volume":"23","author":"Ozbek","year":"2009","journal-title":"Journal of Endourology \/ Endourological Society"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0775","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly","volume":"15","author":"Pacher","year":"2018","journal-title":"Nature Reviews. Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0780","first-page":"625","article-title":"Alcohol Binge-Induced Cardiovascular Dysfunction Involves Endocannabinoid\u2013CB1-R Signaling","volume":"4","author":"Paloczi","year":"2019","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0785","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1590\/1414-431X20133061","article-title":"Morphometric evaluation of nitric oxide synthase isoforms and their cytokine regulators predict pulmonary dysfunction and survival in systemic sclerosis","volume":"46","author":"Parra","year":"2013","journal-title":"Brazilian Journal of Medical and Biological Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0790","first-page":"20","article-title":"Efficacy of rimonabant in obese patients with binge eating disorder","volume":"121","author":"Pataky","year":"2013","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0795","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2119\/molmed.2011.00149","article-title":"Cannabinoid receptor type I modulates alcohol-induced liver fibrosis","volume":"17","author":"Patsenker","year":"2011","journal-title":"Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0800","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm1001-1138","article-title":"Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle","volume":"7","author":"Perreault","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0805","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1463-1326.2009.01133.x","article-title":"Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes","volume":"12","author":"Perwitz","year":"2010","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0810","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012841","article-title":"Hepatitis C virus induces the cannabinoid receptor 1","volume":"5","author":"van der Poorten","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0820","doi-asserted-by":"crossref","first-page":"87ra53","DOI":"10.1126\/scitranslmed.3001725","article-title":"The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis","volume":"3","author":"Pullamsetti","year":"2011","journal-title":"Science Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0825","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2337\/db11-0477","article-title":"Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy","volume":"61","author":"Rajesh","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0830","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1476-5381.2010.00712.x","article-title":"Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells","volume":"160","author":"Rajesh","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0835","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bbrc.2008.10.159","article-title":"Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation","volume":"377","author":"Rajesh","year":"2008","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0840","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.pbb.2010.07.021","article-title":"The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior","volume":"97","author":"Randall","year":"2010","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0845","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","article-title":"Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice","volume":"284","author":"Ravinet Trillou","year":"2003","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0850","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bmcl.2009.12.003","article-title":"Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier","volume":"20","author":"Receveur","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0855","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1586\/ecp.12.74","article-title":"Polypharmacology: drug discovery for the future","volume":"6","author":"Reddy","year":"2013","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0860","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0014-2999(97)89665-3","article-title":"Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone","volume":"327","author":"Rice","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0865","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0870","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-3565(25)20674-7","article-title":"Characterization of two cloned human CB1 cannabinoid receptor isoforms","volume":"278","author":"Rinaldi-Carmona","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0875","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/adb.12508","article-title":"Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation","volume":"23","author":"Robinson","year":"2018","journal-title":"Addiction Biology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0880","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI117769","article-title":"Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility","volume":"95","author":"Rockey","year":"1995","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0885","first-page":"G260","article-title":"Regulation of inducible nitric oxide synthase in hepatic sinusoidal endothelial cells","volume":"271","author":"Rockey","year":"1996","journal-title":"The American Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0890","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/path.1116","article-title":"iNOS gene upregulation is associated with the early proliferative response of human lung fibroblasts to cytokine stimulation","volume":"197","author":"Romanska","year":"2002","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0895","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/gast.2002.30305","article-title":"Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat","volume":"122","author":"Ros","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0900","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc08-0386","article-title":"SERENADE: the study evaluating rimonabant efficacy in drug-naive diabetic patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0905","doi-asserted-by":"crossref","first-page":"9874","DOI":"10.1021\/jm4010708","article-title":"6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds","volume":"56","author":"R\u00f6ver","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0910","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1172\/JCI83626","article-title":"Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages","volume":"127","author":"Ruiz de Azua","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0915","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.febslet.2004.11.085","article-title":"Identification and characterisation of a novel splice variant of the human CB1 receptor","volume":"579","author":"Ryberg","year":"2005","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0920","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bmcl.2010.10.055","article-title":"Novel pyrazole-3-carboxamide derivatives as cannabinoid-1 (CB1) antagonists: journey from non-polar to polar amides","volume":"21","author":"Sasmal","year":"2011","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0925","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1099\/vir.0.067231-0","article-title":"Endocannabinoid CB1 antagonists inhibit hepatitis C virus production, providing a novel class of antiviral host-targeting agents","volume":"95","author":"Shahidi","year":"2014","journal-title":"The Journal of General Virology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0930","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijcard.2015.11.040","article-title":"Overexpression myocardial inducible nitric oxide synthase exacerbates cardiac dysfunction and beta-adrenergic desensitization in experimental hypothyroidism","volume":"204","author":"Shao","year":"2016","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0935","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature20613","article-title":"High-resolution crystal structure of the human CB1 cannabinoid receptor","volume":"540","author":"Shao","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0940","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/jcmm.13523","article-title":"Blockade of cannabinoid 1 receptor improves glucose responsiveness in pancreatic beta cells","volume":"22","author":"Shin","year":"2018","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0945","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1074\/jbc.270.8.3726","article-title":"An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing","volume":"270","author":"Shire","year":"1995","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0950","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.drudis.2018.01.029","article-title":"Peripheral modulation of the endocannabinoid system in metabolic disease","volume":"23","author":"Shrestha","year":"2018","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0955","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s12020-016-1172-6","article-title":"Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance","volume":"55","author":"Sidibeh","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0960","doi-asserted-by":"crossref","first-page":"R309","DOI":"10.1530\/EJE-16-1044","article-title":"MECHANISMS IN ENDOCRINOLOGY: endocannabinoids and metabolism: past, present and future","volume":"176","author":"Simon","year":"2017","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0965","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00109-013-1034-0","article-title":"Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome","volume":"91","author":"Slavic","year":"2013","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0970","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/ijo.2009.253","article-title":"Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control","volume":"34","author":"Son","year":"2010","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0975","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","article-title":"Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial","volume":"28","author":"Soyka","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0980","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S2213-2600(17)30122-4","article-title":"Clinical trial research in focus: why do so many clinical trials fail in IPF?","volume":"5","author":"Spagnolo","year":"2017","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0985","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1189\/jlb.3HI1214-584R","article-title":"Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors","volume":"99","author":"Staiano","year":"2016","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0990","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1111\/j.1476-5381.2011.01744.x","article-title":"Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones","volume":"165","author":"Straiker","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb0995","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3748\/wjg.v16.i11.1321","article-title":"Alcoholic liver disease and the gut-liver axis","volume":"16","author":"Szabo","year":"2010","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1000","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/syn.21721","article-title":"Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study","volume":"68","author":"Takano","year":"2014","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/jbcpp-2015-0055","article-title":"The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases","volume":"27","author":"Tam","year":"2016","journal-title":"Journal of Basic and Clinical Physiology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.24077","article-title":"Endocannabinoids in liver disease","volume":"53","author":"Tam","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1020","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.molmet.2017.06.010","article-title":"Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling","volume":"6","author":"Tam","year":"2017","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1025","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1172\/JCI42551","article-title":"Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity","volume":"120","author":"Tam","year":"2010","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1030","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1530-0277.2009.00946.x","article-title":"Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage","volume":"33","author":"Tang","year":"2009","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb3015","doi-asserted-by":"crossref","first-page":"e42134","DOI":"10.1371\/journal.pone.0042134","article-title":"Beneficial Metabolic Effects of CB1R Anti-Sense Oligonucleotide Treatment in Diet-Induced Obese AKR\/J Mice","volume":"7(8)","author":"Tang","year":"2012","journal-title":"Plos One"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1035","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.2337\/db07-1623","article-title":"Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes","volume":"57","author":"Tedesco","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1040","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis","volume":"12","author":"Teixeira-Clerc","year":"2006","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1050","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jc.2011-2486","article-title":"Does rimonabant independently affect free fatty acid and glucose metabolism?","volume":"97","author":"Triay","year":"2012","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1055","article-title":"Dual inhibition of cannabinoid-1 receptor and iNOS attenuates obesity-induced chronic kidney disease","author":"Udi","year":"2019","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1060","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1681\/ASN.2016101085","article-title":"Proximal tubular cannabinoid-1 receptor regulates obesity-induced CKD","volume":"28","author":"Udi","year":"2017","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1065","first-page":"320","article-title":"Feasibility evaluation of myocardial cannabinoid type 1 receptor imaging in obesity: a translational approach","volume":"11","author":"Valenta","year":"2018","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1070","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.pharmthera.2020.107477_bb2005","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","article-title":"Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study","volume":"29","author":"Van Gaal","year":"2008","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1075","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1096\/fasebj.12.11.1035","article-title":"Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension","volume":"12","author":"Varga","year":"1998","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1080","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ijo.2011.171","article-title":"Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors","volume":"36","author":"Vijayakumar","year":"2012","journal-title":"International Journal of Obesity"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1085","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/S0735-1097(01)01671-0","article-title":"Endogenous cannabinoids mediate hypotension after experimental myocardial infarction","volume":"38","author":"Wagner","year":"2001","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1090","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/37371","article-title":"Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock","volume":"390","author":"Wagner","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1095","article-title":"Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1535370213514922","article-title":"The peripheral cannabinoid receptor 1 antagonist VD60 efficiently inhibits carbon tetrachloride-intoxicated hepatic fibrosis progression","volume":"239","author":"Wei","year":"2014","journal-title":"Experimental Biology and Medicine (Maywood, N.J.)"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2016.10.048","article-title":"Alcohol abuse and cardiac disease","volume":"69","author":"Whitman","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1110","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/mp200617z","article-title":"Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists","volume":"9","author":"Wittgen","year":"2012","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"The Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.brainres.2008.08.027","article-title":"Similar in vitro pharmacology of human cannabinoid CB1 receptor variants expressed in CHO cells","volume":"1238","author":"Xiao","year":"2008","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1125","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.aaa0079","article-title":"Metabolism. S-Nitrosylation links obesity-associated inflammation to endoplasmic reticulum dysfunction","volume":"349","author":"Yang","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107477_bb1130","doi-asserted-by":"crossref","first-page":"10276","DOI":"10.1021\/acs.jmedchem.8b01467","article-title":"6-benzhydryl-4-amino-quinolin-2-ones as potent cannabinoid type 1 (CB1) receptor inverse agonists and chemical modifications for peripheral selectivity","volume":"61","author":"Zhang","year":"2018","journal-title":"Journal of Medicinal Chemistry"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582030005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:04:16Z","timestamp":1759010656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582030005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":227,"alternative-id":["S016372582030005X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107477","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic potential of second and third generation CB1R antagonists","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107477"}}